

# PharmaPendium®

## Release notes: New homepage and new PDF viewer for faster access to drug information

May 2023

Dear valued customers,

we are thrilled to announce the latest update to PharmaPendium, which includes several new and exciting features designed to make your work more efficient and effective.

### New homepage for more convenient access

Our new homepage will make it more convenient for you to access critical information around drugs, targets, indications, and drug-target-mechanism of action relationships for a quicker and more accurate toxicity profiling for your drug candidates.

The screenshot displays the PharmaPendium homepage layout. At the top, the PharmaPendium logo is on the left, and a 'Quick search' bar is on the right, with the text 'access millions of regulatory documents in just seconds' below it. Below the search bar is a 'Quick text search' input field with the example 'e.g. "heart attack" AND stress' and a 'Search >' button. To the left of the search bar is a 'Limit to' dropdown and a checkbox for 'Include synonyms'. To the right is a link for 'Advanced search text'. Below the search bar is a section titled 'Info pages' with the description 'review regulatory data by searching for specific drugs, drug-targets, indications, or adverse effects'. This section contains four icons: 'Drugs', 'Adverse effects & toxicity', 'Targets', and 'Indications'. Below the 'Info pages' section is a 'Datasets' section with the description 'for unparalleled accuracy, access expertly curated and normalized data on your area of expertise'. This section contains seven icons: 'Drug safety', 'FAERS', 'Pharmacokinetic', 'Metabolizing enz. & transporters', 'Efficacy', 'Activity', and 'Chemistry search'. Below the 'Datasets' section is a 'Predictive tools' section with the description 'predict and visualize the risk of drug-drug interactions and off-target related adverse events'. This section contains three icons: 'DDI risk calculator v1.0', 'DDI risk calculator v2.0', and 'Safety margin'. At the bottom of the page is the Elsevier logo and a footer containing 'Terms and conditions', 'Privacy policy', and 'Support Center'. Below the footer is a copyright notice: 'Copyright © 2023 Elsevier Limited except certain content provided by third parties. PharmaPendium is a trademark of Elsevier Limited. We use cookies to help provide and enhance our services and tailor content. By continuing you agree to the use of cookies'.

Moreover, this new homepage will allow you to make more accurate requests directly from your sources of choices (e.g., select EMA and FDA only) or select the years of interest (e.g., 2011 to 2021).



PharmaPendium

Quick search access millions of regulatory documents in just seconds

Quick text search e.g. "heart attack" AND stress

Search >

Limit to ☒ Include synonyms [Advanced search text](#)

☐ Publication years From 2023 To 2023

Sources: [Deselect all](#)

<input checked="" type="checkbox"/> FDA approval packages	<input checked="" type="checkbox"/> DESI documents
<input checked="" type="checkbox"/> EMA approval documents	<input checked="" type="checkbox"/> Meyler's 16th Edition
<input checked="" type="checkbox"/> FDA Advisory Committee Documents	<input checked="" type="checkbox"/> Mosby's Drug Consult™

Info pages review regulatory data by searching for specific drugs, drug-targets, indications, or adverse effects



Drugs



Adverse effects & toxicity



Targets

**Indications** >

Examine the adverse effects-indications relationship across specific drugs or drug classes from pre-clinical to post-market stages

Datasets for unparalleled accuracy, access expertly curated and normalized data on your area of expertise



## Upgrade of all the information pages including a new, enhanced pdf viewer

- The upgraded pages offer enhanced search and function capabilities such as the ability to see the numbers of searched terms by subcategories of approval documents. These pages also include a direct link to the drug of interest.
- The new pdf viewer will allow you to search for multiple terms simultaneously, making it easier and quicker to find the relevant information. In addition, you can now add annotations and drawings directly to the PDF, allowing you to highlight and mark up important information for later reference.

- *“When was a proprietary name submitted for consideration and denied?”*
- *“How was this issue discussed with regulatory agencies?”*

The screenshot displays the PharmaPendium website interface. At the top, there's a navigation bar with links like "Browse", "Search", "My tools", "Modules", and user options "Register" and "Sign in". The main content area is titled "FDA approval package" and shows search results for "Administrative documents 125409/S-000 Part 07". A sidebar on the left lists "Administrative documents (1)" with details about a February 2012 meeting. The main document viewer shows a PDF page with highlighted text and red annotations. Red circles highlight specific terms like "pertuzumab", "alternate name", and "AGREEMENT REACHED:". Red arrows point from the search criteria "Search this FDA package reconsideration name" to the search results and from the sidebar entry to the document viewer.

**PharmaPendium**

Browse Search My tools Modules ? [Bell Icon] [Home Icon]

[Register] [Sign in]

## FDA approval package

Search this FDA package  
reconsideration name

1 match found (including synonyms)

- Administrative documents (1)
  - 24-Feb-2012
    - Administrative documents 125409/...

... from FDA. a) Would it be possible to submit a Request for Reconsideration of the Proprietary Name for ...

... : LOCATION: APPLICATION: DRUG NAME: TYPE OF MEETING: April 12, 2012 4:00 p.m. EST Telecon BLA 125409 ...

... , 2012 TIME: 3:30 4:00pm APPLICATION:BLA 125409 DRUG NAME: Pertuzumab TYPE OF MEETING: T-con MEETING ...

... BACKGROUND: (b)(4) The sponsor submitted aPN review request for under BLA 125409 on Jan. 6, 2012. The name ...

Pertuzumab > Administrative documents > Administrative documents 125409/S-000 Part 07

## Administrative documents 125409/S-000 Part 07

Drug info

16 of 35 Automatic Zoom

alternate name

< > Highlight All Match Case Match Diacritics Whole Words 4 of 19 matches

before.




3) As an alternative contingency plan, would it be possible to launch the drug as pertuzumab similar to how AstraZeneca launched with vandetanib before waiting for the trade name approval of CAPRELSA? YES




**AGREEMENT REACHED:**  
FDA/DMEPA encouraged the sponsor to submit the Alternate name for review asap.  
DMEPA also made the following points:  
Every effort will be made to review the alternate name, but there is no guarantee that the name will be reviewed by PDUFA date of 6/8/12 (~ 2 months from now); if this be the case, we will promptly inform them.

This document shows original U.S. government data provided by the U.S. Food & Drug Administration and is available in the public domain.  
Reference ID: 3125564 has been processed to facilitate searching and data extraction and may be viewed at www.pharmapendium.com



Here are all the new features of the PDF viewer:


#	Feature name	Visual
1.	Number of hits per subcategories	
2.	Drug info link	
3.	Search with multiple terms	

4.	Rotation of documents	
5.	Presentation mode	
6.	Spread view both add and even: > to compare side by side tables or figures	


7. Annotation with text and drawing





8. Convenient and automatic zoom modes



9. Document properties





10.	Different options for page scrolling	
11.	Tablet friendly	

We believe that these new features will significantly improve your experience with PharmaPendium and help you to perform your work more efficiently and effectively.

We look forward to providing you with even more innovative features in the future.

For any feedback or questions, reach out to us:

[pharmabiotechEH@elsevier.com](mailto:pharmabiotechEH@elsevier.com)

Best regards from the team:

Thomas, Sakshi, Olivier, Ahmet, Jacco, Abhijeet, Vitaly, Shweta, Mikhail, Willem, Khushboo, Sreekantha, Aliaksandr, Branka, Jose, Igor, Iaroslav, Arseny, Canberk, Shakhriyor, Boudewijn